Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

x patients decreased during treatment with MT103, with a complete clearance of tumor cells from the bone marrow in three patients and partial clearance in the other two patients.

Complete and partial clinical responses were assessed according to Cheson criteria, and all responses were confirmed by a central review. Clinical responses and tumor clearance from the bone marrow demonstrate clinical activity of the BiTE antibody in those patients who received higher doses.

"We are pleased to see the number of objective responses to MT103 in a relapsed patient population, and are looking forward to providing a more detailed update at ASH about our exciting new clinical data with the first BiTE antibody in clinical trials," commented Christian Itin, Ph.D., President and Chief Executive Officer of Micromet.

MT103 is a novel, highly-specific and highly-potent drug, with which objective responses are being seen in patients with FL and MCL who have progressed after multiple prior treatments. The most common adverse events observed in this study were fever, chills, leukopenia, lymphopenia, pyrexia and elevated liver enzymes. The majority of the adverse events have been fully reversible and in many cases resolved without discontinuation of MT103 administration. Less common adverse events included central nervous system events, which were fully reversible after discontinuation of the infusion. Dose escalation continues.

"These clinical responses to MT103 in patients with various B-cell malignancies are an important achievement in our partnership with Micromet,'' commented Dirk Reitsma, M.D., vice president, clinical development, oncology, MedImmune. "The expansion of research into the potential of BiTE technology in a clinical setting represents another pioneering effort by MedImmune to develop novel targeted cancer treatments for patients in need."

About BiTE(R) Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, o
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The ... GHz, 7Gbps Wi-Fi, Wireless Gigabit Alliance, Access Points, ... Business Models, Technology Roadmap and Analysis (2014 - ... of the overall market, segmented by WiGig enabled ... major sub segments of the WiGig market, and ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 Agoura Hills ... special promotion on Zoom Whitening. Zoom Whitening is one of ... only available through a dental professional. This light-assisted treatment uses ... the structure of the tooth to break up stains that ... effective on coffee, tea, wine, soft drink and tobacco stains. ...
(Date:7/25/2014)... July 25, 2014 Health Advocate™, Inc., ... a subsidiary of West Corporation, is introducing its newest ... Reduce Costs and Enhance Quality. , The webinar will ... AM ET and again at 2 PM ET. For ... visit http://www.HealthAdvocate.com/Analytics or call 866.799.2655. , In ...
(Date:7/25/2014)... patients could be treated more quickly after Manchester ... (ECG) and blood test on arrival, is effective ... a new study shows., The findings of a ... Medicine Journal, could potentially make a huge difference ... is the most common reason for emergency hospital ...
(Date:7/25/2014)... on the horizon. Bacteria that produce a therapeutic ... resistance and other adverse effects of a high-fat ... , "Of course it,s hard to speculate from ... Ph.D., assistant professor of Pharmacology. "But essentially, we,ve ... in mice, even though they,re eating a high-fat ...
Breaking Medicine News(10 mins):Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2
... , WEDNESDAY, Sept. 14 (HealthDay News) -- ... new research suggests that people who kick the habit ... from the University of Missouri found that smoking is ... (often being emotionally negative and anxious) among adults under ...
... Alexandria, Va., USA - The International and American ... proceedings from the 3rd AADR Fall Focused Symposium ... symposium was held November 12-13, 2010, in Washington, ... Symposium under the objective to provide networking opportunities ...
... Division of Pain Medicine in the Department of ... Neurological Institute have each received 2011 Medical & ... Institutions for these nationally competitive awards are reviewed ... comprised of leaders in the field. The ...
... likely than Caucasians to be not only diagnosed with head and ... answer isn,t a simple one, differences in lifestyle, access to care ... a new study from Henry Ford Hospital. The study also ... current smokers, one of the primary risk factors for head and ...
... , WEDNESDAY, Sept. 14 (HealthDay News) -- For ... on staff, "telestroke" may be a cost-effective option to ... say. Telestroke, or virtual stroke care, ... through two-way audio-video equipment. "In an era of ...
... The human papillomavirus (HPV) is more likely to be ... and those with private health insurance, according to a new ... also reveals that laryngeal cancer patients with Medicare, who tend ... HPV, suggesting that HPV infection may be closely tied to ...
Cached Medicine News:Health News:Quitting Smoking May Improve Personality, Study Suggests 2Health News:IADR/AADR publish proceedings from the AADR Fall Focused Symposium on Salivary Diagnostics 2Health News:Genetics, lifestyle provide clues to racial differences in head and neck cancer 2Health News:Genetics, lifestyle provide clues to racial differences in head and neck cancer 3Health News:Rural Stroke Victims May Benefit From 'Virtual' Care 2Health News:Gender, insurance type tied to HPV infection in laryngeal cancer patients 2Health News:Gender, insurance type tied to HPV infection in laryngeal cancer patients 3
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... YORK, Dec. 7, 2011 Reportlinker.com announces ... available in its catalogue: ... Japan http://www.reportlinker.com/p0702529/Future-Therapeutic-Drug-Monitoring-Market-US-Europe-Japan.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... TDM market will undergo significant transformation. These ...
... Talyst announces AutoPharm® Mobile, an Apple iOS application ... can be conveniently accessed on an Apple iOS ... across the health system. AutoPharm ... access to medication inventory throughout the health system. ...
Cached Medicine Technology:Future Therapeutic Drug Monitoring Market: US, Europe, Japan 2Future Therapeutic Drug Monitoring Market: US, Europe, Japan 3Future Therapeutic Drug Monitoring Market: US, Europe, Japan 4Future Therapeutic Drug Monitoring Market: US, Europe, Japan 5Future Therapeutic Drug Monitoring Market: US, Europe, Japan 6Future Therapeutic Drug Monitoring Market: US, Europe, Japan 7Future Therapeutic Drug Monitoring Market: US, Europe, Japan 8Future Therapeutic Drug Monitoring Market: US, Europe, Japan 9Talyst Releases AutoPharm Mobile 2
Dust covers for a variety of Zeiss microscopes...
Inquire...
... An economical laboratory tissue culture microscope, ... to expand their applications. Olympus has taken ... the CKX41. Fluorescence can be used with ... images can be carried out on the ...
... Designed for the scientist who wants ... the TE2000E2 is a high precision Z-focus ... This makes it possible to expand ... sources and image outputs. A five-way ...
Medicine Products: